Castle Biosciences stock gets Buy upgrade as EADV data are presented
Castle Biosciences received a "Buy" rating upgrade from Wall Street Zen on September 26, 2026, driven by new DecisionDx-Melanoma data presented at the European Academy of Dermatology and Venereology Congress. The study, involving 2,799 patients, showed a 99.60% five-year recurrence-free survival rate for low-risk patients who did not undergo sentinel lymph node biopsy. This clinical evidence, combined with a strong financial performance in Q2 2026 where revenue exceeded expectations, positions the company favorably.
Castle Biosciences (CSTL) Expands On New Clinical Data, Is It Still 19% Below Fair Value?
Castle Biosciences (CSTL) has seen a significant stock surge of 47.37% in 90 days following new clinical data for its AdvanceAD-Tx atopic dermatitis test, a new Scottsdale lab, and upcoming DecisionDx-Melanoma data. Despite this rise, the company is considered by some analysts to be 19% undervalued with a fair value of $44.00, driven by its expanding test menu and role in precision medicine. However, potential risks include unfavorable payer decisions and rising commercial costs.
Bank of America Corp DE Makes New $2.35 Million Investment in Castle Biosciences, Inc. $CSTL
Bank of America Corp DE has invested $2.35 million in Castle Biosciences, acquiring 98,745 shares, giving them a 0.32% stake. This comes as Castle Biosciences exceeded quarterly revenue and earnings expectations, with analysts maintaining a "Moderate Buy" rating and an average price target of $42. Despite the institutional interest, insiders have recently sold 178,432 shares worth $5.64 million.
Castle Biosciences CCO Executes 6,577-Share Sale Under Rule 10b5-1 Plan
Tobin W. Juvenal, the Chief Commercial Officer of Castle Biosciences Inc. (NASDAQ: CSTL), sold a total of 6,577 shares of common stock on September 29 and 30, 2026. These sales were conducted under a pre-established Rule 10b5-1 trading plan adopted on May 28, 2026. After these transactions, Juvenal retained 52,007 shares of common stock.
Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 5,543 Shares of Stock
Castle Biosciences insider Tobin Juvenal sold 5,543 shares of the company's stock for approximately $196,777, reducing his ownership by 9.46% to 53,041 shares. This transaction occurred under a pre-arranged Rule 10b5-1 plan on September 29th. The company recently reported better-than-expected quarterly revenue and adjusted loss per share, and analysts maintain a "Moderate Buy" rating with an average price target of $42.00.
Officer Kristen Oelschlager proposes selling 4,153 Castle Biosciences (CSTL) shares.
Kristen Oelschlager, an officer at Castle Biosciences Inc. (CSTL), has proposed selling 4,153 common shares valued at $147,556.09 through Morgan Stanley Smith Barney LLC, with an approximate sale date of October 1, 2026. This proposed sale is associated with a cash exercise of stock options with the issuer. The filing also details Oelschlager's prior sales in August and September 2026, alongside other recent insider sales by The Fritz Shorter Trust.
Low-risk melanoma patients who skipped lymph node biopsy had 99.6% recurrence-free survival at five years.
Castle Biosciences will present new DecisionDx-Melanoma study findings at the EADV Congress 2026, demonstrating that low-risk patients who forgo sentinel lymph node biopsy (SLNB) achieve a 99.6% five-year recurrence-free survival rate. The data supports using the DecisionDx-Melanoma test to guide SLNB decisions and risk-aligned post-surgical management for melanoma patients, including those with transected biopsies where staging is uncertain. The test also effectively stratifies recurrence risk in early-stage patients, identifying those who may need closer surveillance despite traditional staging.
Learn Why The Bull Case For Castle Biosciences (CSTL) Could Change Following Test Guided Care Decisions
Castle Biosciences (CSTL) recently released new clinical data for its TissueCypher Barrett's Esophagus test, showing significant changes in patient management, and for its AdvanceAD-Tx atopic dermatitis test, along with opening a new lab. These developments strengthen the clinical case for its diagnostic tests, but the long-term investment narrative depends on scale, reimbursement clarity, and broad test adoption. Analysts project substantial revenue and earnings growth by 2029, yet reimbursement risk remains a key concern.
Texas bioscience firm expands in Scottsdale as AZ headcount tops 200
Castle Biosciences, a Texas-based molecular diagnostics firm, is expanding its operations in Scottsdale, Arizona, with a new office and laboratory. The company is leasing 55,000 square feet in the Perimeter Center to accommodate growth and support its work for patients and clinicians. This expansion further solidifies Castle Biosciences' presence in Arizona, where its headcount has now exceeded 200.
A test changed doctors’ plans for 90% of patients with the same precancerous esophagus condition. Their risks differed.
A new study by Castle Biosciences (CSTL) found that its TissueCypher® Barrett's Esophagus Test changed management recommendations for 90% of patients with non-dysplastic Barrett's esophagus. The test stratified patients by risk of progression to high-grade dysplasia or esophageal adenocarcinoma, leading clinicians to escalate care for high-risk individuals and de-escalate for low-risk patients. This highlights the test's utility in personalizing patient management for a precancerous condition where traditional methods often fail to distinguish true risk.
Castle Biosciences CEO sells $512k in stock
Castle Biosciences Inc. CEO Derek J. Maetzold sold 14,496 shares of common stock for $512,201 on September 21, 2026, as part of a Rule 10b5-1 plan. Despite the stock appearing overvalued according to InvestingPro, Maetzold also acquired 8,580 shares through stock options on the same day. This transaction follows recent strong Q2 results for Castle Biosciences, which exceeded Wall Street expectations for both profit and revenue, leading BTIG to raise its price target for the company.
Form 4 Castle Biosciences Inc For: 26 September By Investing.com
This article announces the filing of Form 4 for Castle Biosciences Inc., pertaining to actions on September 26. It is a brief, factual announcement from Investing.com, typical of regulatory filing news. The article itself contains minimal direct content about the filing, primarily serving as a placeholder for the announcement within a financial news portal.
Form 4 Castle Biosciences Inc For: 26 September By Investing.com
This article reports on a Form 4 filing for Castle Biosciences Inc. on September 26, as published by Investing.com. It indicates general news rather than specific details of the filing, and features market data for various indices, commodities, and shares, as well as popular news headlines from the financial world.
What Is Castle Biosciences (CSTL) Signaling With Its New Atopic Dermatitis Study?
Castle Biosciences (CSTL) recently released new study data for its AdvanceAD-Tx test, a molecular diagnostic for atopic dermatitis, indicating strong patient interest and an unmet clinical need for personalized treatments. This study supports Castle Biosciences' strategy to expand its test menu into new disease areas beyond skin cancers, aiming to diversify revenue and tap into larger patient populations. However, the company still faces challenges regarding payer coverage and potential reimbursement risks for new tests.
Castle Biosciences (NASDAQ:CSTL) Upgraded to "Buy" at Wall Street Zen
Wall Street Zen has upgraded Castle Biosciences (NASDAQ:CSTL) from a "hold" to a "buy" rating. This upgrade follows the company's strong quarterly performance, where it exceeded revenue expectations with $99.86 million and reported a lower-than-expected adjusted loss of $0.07 per share. Despite significant insider selling, institutional ownership remains high, indicating confidence from major investors.
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
A new study by Castle Biosciences (CSTL) found that 55% of atopic dermatitis patients who used targeted systemic therapies changed treatment due to lack of efficacy. The assessment revealed that 83% of all respondents, and 94% of those open to new systemic therapies, were interested in molecular testing to guide treatment selection. This highlights the need for tools like Castle's AdvanceAD-Tx, which personalizes treatment based on a patient's underlying disease biology.
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 8,580 Shares
Castle Biosciences insider Derek Maetzold sold 8,580 shares of the company's stock for approximately $303,131, reducing his direct stake by 28.54%. The transaction was made under a pre-arranged Rule 10b5-1 plan. Despite the insider sale, analysts maintain a "Moderate Buy" rating for Castle Biosciences, with the stock trading near its 52-week high after exceeding revenue and earnings expectations in its latest quarter.
Castle Biosciences opens 55,000 sq ft Arizona lab facility
Castle Biosciences Inc. has announced the opening of a new 55,000-square-foot laboratory and office facility in Scottsdale, Arizona, expanding its operational footprint in the Phoenix metropolitan area. The company plans a grand opening celebration on October 6, 2026, and the facility includes advanced infrastructure and employee amenities. Castle Biosciences, which focuses on dermatologic and gastroenterological disease testing, employs over 1,000 people nationally, with approximately 220 in the greater Phoenix area.
Castle Biosciences to Open New Laboratory Facility in Scottsdale
Castle Biosciences is opening a new 55,000-square-foot laboratory and office facility in Scottsdale, Arizona, to accommodate growing test volumes and support long-term growth. The new facility, located in the Perimeter Center business park, includes upgraded infrastructure and employee-focused amenities, reflecting the company's continued investment in its Arizona operations and workforce. A grand opening celebration is scheduled for October 6, 2026, with government and community leaders expected to attend.
Castle Biosciences (NASDAQ: CSTL) Chief Commercial Officer Juvenal Tobin W Sells 6,600 Shares Between $32.32 and $35.14
Castle Biosciences' Chief Commercial Officer, Juvenal Tobin W, sold a total of 6,600 shares in two open-market transactions on September 14 and 15, 2026, at prices ranging from $32.32 to $35.14 per share. Following these sales, Tobin W now holds 58,584 shares, representing approximately 10.1% of his previous holdings. This provides investors with insight into his updated ownership stake in the company.
Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,294 Shares of Stock
Castle Biosciences insider Tobin Juvenal sold 3,294 shares of the company's stock for approximately $115,751 on September 15th, reducing his position by 5.32%. Despite this insider sale, the company recently reported strong quarterly revenue and an adjusted loss per share that exceeded analyst expectations. Analysts generally maintain a "Moderate Buy" rating for CSTL with an average price target of $42.
Tobin Juvenal Sells 3,306 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
Tobin Juvenal, an insider at Castle Biosciences (NASDAQ:CSTL), sold 3,306 shares of the company's stock on September 14th, 2026, for approximately $106,850. This transaction reduced his total holdings by 5.07% to 61,878 shares. Despite the insider sale, analysts have a "Moderate Buy" consensus rating for CSTL with an average price target of $42.00, following the company's Q2 earnings which surpassed revenue and EPS estimates.
Castle Biosciences TissueCypher Study Shows Improved Risk-Aligned Barrett’s Esophagus Management
A new decision modeling study by Castle Biosciences (NASDAQ: CSTL) indicates that its TissueCypher test can significantly improve risk-aligned management decisions for patients with Barrett's esophagus. The study found that incorporating TissueCypher results increased appropriate treatment decisions from 59.8% to 75.3%, notably reducing both undertreatment in progressing patients and overtreatment in non-progressing patients. While the study highlights the test's potential clinical utility, it was based on modeling rather than actual patient outcomes, suggesting a need for future real-world studies.
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Moderate Buy" from Brokerages
Castle Biosciences (NASDAQ:CSTL) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $42.00. The company recently surpassed quarterly earnings expectations, reporting a smaller loss per share and higher revenue than anticipated. Despite institutional investors increasing their stakes, company insiders have sold a significant number of shares.
Responsive Playbooks and the CSTL Inflection
This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL), identifying a near-term weak sentiment within a broader long-term weak bias, despite mid-term strength. It highlights an exceptional risk-reward short setup and outlines three distinct AI-generated trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Short Strategy. The analysis also provides multi-timeframe signal analysis, including support and resistance levels for various time horizons.
SciBase receives additional order from Castle Biosciences, advancing the collaboration
SciBase has received an additional order worth approximately $0.6 million from Castle Biosciences. This order accelerates an ongoing clinical study and prepares for a second study focused on predicting relapses in atopic dermatitis using SciBase's Nevisense Go pen device and electrodes. The collaboration, which began in 2025, aims to expand effective therapies for patients with skin barrier dysfunctions, with deliveries expected to start in Q4 2026.
Bank of New York Mellon Corp Invests $2.34 Million in Castle Biosciences, Inc. $CSTL
Bank of New York Mellon Corp has acquired a new position in Castle Biosciences, Inc. (NASDAQ:CSTL), purchasing 98,018 shares valued at approximately $2.34 million in the second quarter. This investment makes Bank of New York Mellon Corp own about 0.32% of Castle Biosciences. Other institutional investors like Vanguard Group Inc., RTW Investments LP, and Dimensional Fund Advisors LP also adjusted their stakes in the company, while company insiders made significant share sales.
Castle Biosciences COO Oelschlager sells $138,642 in shares By Investing.com
Castle Biosciences Inc. COO Kristen M. Oelschlager sold 4,152 shares of company stock for $138,642 on September 1, 2026, following the exercise of stock options. The sales were conducted under a Rule 10b5-1 trading plan. Despite the stock's strong 44% return over the past year, InvestingPro analysis suggests it is slightly overvalued.
Castle Biosciences, Inc. $CSTL Shares Sold by Bank of America Corp DE
Bank of America Corp DE significantly reduced its stake in Castle Biosciences, selling 195,209 shares and retaining 67,810 shares. Despite this, institutional investors collectively hold 92.6% of the company's stock. Castle Biosciences reported better-than-expected quarterly earnings and revenue, though company insiders have sold a substantial number of shares recently.
Castle Biosciences COO Oelschlager sells $138,642 in shares
Kristen M. Oelschlager, COO of Castle Biosciences Inc. (NASDAQ:CSTL), sold 4,152 shares of common stock for $138,642 on September 1, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan. The company recently reported strong second-quarter results, exceeding revenue and profit expectations, with BTIG raising its price target to $44.
Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares
Tobin W. Juvenal, Chief Commercial Officer at Castle Biosciences Inc. (NASDAQ:CSTL), recently sold 1,730 shares of the company's common stock for $51,190. This transaction was part of a Rule 10b5-1 trading plan. Despite the company not being profitable in the last twelve months, it has shown strong recent returns and exceeded Q2 profit and revenue expectations, leading BTIG to raise its price target.
Empowered Funds LLC Acquires New Shares in Castle Biosciences, Inc. $CSTL
Empowered Funds LLC recently acquired 142,338 shares of Castle Biosciences, Inc. (NASDAQ:CSTL) worth approximately $3.4 million, making them a new institutional investor in the company, which is 92.6% institutionally owned. Castle Biosciences has also reported stronger-than-expected quarterly results, beating analyst estimates for both earnings per share and revenue. Despite a "Moderate Buy" consensus rating from analysts, company insiders have sold a significant number of shares recently.
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $412,609.60 in Stock
Castle Biosciences insider Derek Maetzold sold 12,428 shares of the company's stock, totaling approximately $412,610, reducing his ownership by over 36%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, analysts have a "Moderate Buy" rating with an average price target of $42.00, and institutional investors hold a significant portion of the stock.
Man Group plc Takes $2.59 Million Position in Castle Biosciences, Inc. $CSTL
Man Group plc has acquired a new stake worth $2.59 million in Castle Biosciences, Inc., purchasing 108,761 shares in the second quarter of 2026. This investment makes Man Group plc a 0.36% owner of Castle Biosciences, a company where institutional investors and hedge funds collectively hold 92.6% of the stock. Despite a generally positive "Moderate Buy" consensus rating from analysts and strong quarterly earnings that beat estimates, company insiders have recently sold a significant number of shares.
3,291,963 Shares in Castle Biosciences, Inc. $CSTL Purchased by BlackRock Inc.
BlackRock Inc. has purchased 3,291,963 shares of Castle Biosciences, Inc. (NASDAQ:CSTL) worth approximately $78.5 million, giving it a 10.78% stake in the company. This acquisition comes as Castle Biosciences reported better-than-expected quarterly earnings, with a loss of $0.07 per share against an anticipated $0.41 loss and revenue of $99.86 million. Institutional investors now collectively own 92.6% of the company, while company insiders have recently sold nearly 170,000 shares.
Castle Biosciences, Inc. $CSTL Shares Acquired by Algert Global LLC
Algert Global LLC significantly increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 102.7% in the second quarter, acquiring 35,700 additional shares to reach a total of 70,478 shares valued at $1.68 million. This move is part of broader institutional investor activity, with these entities collectively owning 92.6% of the company. Analysts generally hold a positive outlook for Castle Biosciences, with a consensus "Moderate Buy" rating and an average price target of $42.00, while the company also reported strong Q2 earnings, beating both revenue and EPS estimates.
Castle Biosciences CCO Tobin Juvenal Sells 9,050 Shares via Rule 10b5-1 Plan
Castle Biosciences Inc.'s Chief Commercial Officer, Tobin W. Juvenal, sold 9,050 shares of the company's common stock on August 25, 2026. The sale was executed under a pre-established Rule 10b5-1 trading plan at a weighted-average price of $35.04 per share. Following this transaction, Juvenal directly holds 66,914 shares of Castle Biosciences common stock.
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
Castle Biosciences (CSTL) has seen its stock gain 37% recently, and Wall Street analysts project a further upside of 31.5%, with a mean target price of $44. While analysts' price targets should be viewed with skepticism, a low standard deviation in these targets and a strong positive trend in earnings estimate revisions suggest potential for the stock. CSTL also holds a Zacks Rank #2 (Buy), indicating further upside potential based on earnings estimates.
Castle Biosciences CCO Tobin W sells $51,190 in stock
Juvenal Tobin W, Chief Commercial Officer at Castle Biosciences Inc., sold 1,730 shares of the company's common stock for a total of $51,190. This sale was conducted under a Rule 10b5-1 trading plan and occurred amidst a significant rally in the company's stock, which has seen a 64% return over the past year. Despite the sale, Castle Biosciences recently reported strong second-quarter results, beating analyst expectations and raising its full-year sales guidance, leading to a raised price target from BTIG.
Castle Biosciences (NASDAQ: CSTL) CCO lines up sale of 22,500 shares
Castle Biosciences' Chief Commercial Officer, Tobin Juvenal, has filed a Rule 144 notice for the potential sale of 22,500 shares of common stock, valued at $787,500, through Goldman Sachs & Co. LLC. These shares are related to equity compensation awards granted between 2022 and 2025 and are part of a pre-planned selling arrangement compliant with Rule 10b5-1(c). The filing notes 30,549,507 shares outstanding and also reports recent sales by Juvenal in August 2026.
Parkman Healthcare Partners LLC Invests $3.45 Million in Castle Biosciences, Inc. $CSTL
Parkman Healthcare Partners LLC has purchased a new stake of 144,791 shares, valued at approximately $3.45 million, in Castle Biosciences, Inc. The investment firm now owns about 0.47% of the company. This comes as institutional investors collectively hold 92.6% of CSTL, while company insiders have recently sold shares worth $3.84 million.
Castle Biosciences officer plans $841K share sale | CSTL SEC Filing - Form 144
An officer of Castle Biosciences (CSTL), Kristen M. Oelschlager, has filed a Rule 144 notice for a proposed sale of 24,602 shares of common stock, valued at $841,388.40. The shares are held by The Fritz Shorter Trust, with Oelschlager as a trustee, and J.P. Morgan Securities LLC will handle the sale. This filing indicates a neutral impact and sentiment according to Rhea-AI.
Castle Biosciences surges 67% after InvestingPro Fair Value call By Investing.com
Castle Biosciences (NASDAQ:CSTL) saw a remarkable 67% return in three months after InvestingPro's Fair Value analysis identified it as significantly undervalued in May 2026. The stock surged from $18.63 to $34.20, exceeding the initial Fair Value projection of $28.20. This success highlights how systematic Fair Value analysis, which aggregates multiple valuation approaches, can identify mispriced opportunities and provide investors with comprehensive insights into a stock's intrinsic worth.
Castle Biosciences surges 67% after InvestingPro Fair Value call By Investing.com
Castle Biosciences (NASDAQ:CSTL) saw its stock surge by 67% in three months after InvestingPro's Fair Value analysis identified it as significantly undervalued in May 2026. This performance validates the intrinsic value calculations, which projected a 51% upside from its $18.63 trading price at the time. The company's strong Q2 2026 earnings, improved EBITDA, and key product milestones further supported the stock's rise.
238,204 Shares in Castle Biosciences, Inc. $CSTL Acquired by Advisors Capital Management LLC
Advisors Capital Management LLC has acquired 238,204 shares of Castle Biosciences, Inc. (NASDAQ:CSTL) worth approximately $5.68 million in the second quarter. This move makes Advisors Capital Management LLC the owner of about 0.78% of Castle Biosciences' stock. The article also details other institutional investor activity, insider transactions, recent price performance, and analyst ratings for the company.
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. announced its participation in two upcoming investor conferences in September 2026. The company's executive management will present at Baird's 2026 Global Healthcare Conference on September 15, 2026, and will be available for one-on-one meetings at the 10th annual Lake Street Best Ideas Growth (BIG10) Conference on September 10, 2026. Castle Biosciences is a diagnostics company focused on improving health through innovative tests in dermatologic and gastroenterological disease.
CFO & Treasurer Of Castle Biosciences Sold 41% Of Their Shares
Castle Biosciences' CFO & Treasurer, Frank Stokes, recently sold US$742k worth of stock, reducing his holding by 41%. This was the largest insider sale in the past year, and while it's generally seen as a negative signal, it doesn't definitively indicate that insiders believe the shares are overvalued. Insiders currently own 2.4% of the company's shares.
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Analysts
Castle Biosciences, Inc. (NASDAQ:CSTL) has received a "Moderate Buy" rating from analysts, with an average 12-month price target of $42.00, significantly above its recent opening price. The company exceeded quarterly revenue and adjusted EPS expectations but remains unprofitable with a negative net margin. Institutional ownership is high at 92.6%, though insiders have recently sold shares under pre-arranged trading plans.
Castle Biosciences CCO Tobin W Juvenal Sells 1,730 Shares via 10b5-1 Trading Plan
Castle Biosciences Inc. Chief Commercial Officer Tobin W Juvenal sold 1,730 shares of company common stock on August 17, 2026, under a pre-established Rule 10b5-1 trading plan. The shares were sold at a weighted-average price of $29.59, with individual transactions ranging from $29.21 to $30.01. Following this sale, Juvenal directly holds 75,964 shares of common stock in Castle Biosciences.
Castle Biosciences CFO Frank Stokes Sells 24,908 Shares in Open Market Transaction
Frank Stokes, CFO of Castle Biosciences Inc. (NASDAQ:CSTL), sold 24,908 shares of company stock in an open market transaction on August 14, 2026. The shares were sold at a weighted-average price of $29.77, with individual trades ranging from $29.71 to $29.97. Following this sale, Stokes retains direct beneficial ownership of 35,177 shares of Castle Biosciences common stock.
